DR info

臨床試験数 : 24 / 薬物数 : 40 - (DrugBank : 18) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 110

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

AZA
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China;
Adalimumab
   Shanghai Zhongshan Hospital
      2020   Phase 4   NCT04300686   China;
Adalimumab Injection
   Chinese SLE Treatment And Research Group
      2022   Phase 4   NCT05151848   China;
Anti-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Autologous Peripheral Blood Stem Cell Transplantation
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
CYC
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China;
Clofarabine
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Computed Tomography
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Cyclophosphamide
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Cyclosporine
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Digital substraction angiography (DSA)
   Shanghai Zhongshan Hospital
      2019   -   NCT04137614   China;
Drug coated balloon (DCB)
   Shanghai Zhongshan Hospital
      2019   -   NCT04137614   China;
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Glucocorticoids
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China;
Glucorticoid Taper Regimen
   Janssen Pharmaceutical K.K.
      2021   Phase 3   NCT04882072   Japan;
Infliximab
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT04564001   -
   Ospedale San Raffaele
      2017   -   NCT03192878   Italy;
Leflunomide
   Shanghai Zhongshan Hospital
      2016   -   NCT03893136   China;
Leflunomide 10mg Tab
   Jiang lindi
      2016   -   NCT02981979   China;
MMF
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China;
MTX
   Chinese SLE Treatment And Research Group
      2017   Phase 3   NCT03096275   China;
Methotrexate Tablets
   Shanghai Zhongshan Hospital
      2020   Phase 4   NCT04299971   China;
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Naltrexone Hydrochloride
   University of Pennsylvania
      2019   Phase 2   NCT03482479   United States;
Placebo
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 3   JPRN-JapicCTI-142616   Japan;
Positron Emission Tomography
   Jonsson Comprehensive Cancer Center
      2016   Early Phase 1   NCT02925351   United States;
Prednisolone
   AbbVie
      2020   Phase 3   NCT04161898   Japan;Korea, Republic of;Turkey;
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006055   United States;
Prednisone, cyclophosphamide
   Chinese Academy of Medical Sciences, Fuwai Hospital
      2018   Phase 2/Phase 3   NCT03550781   -
Remicade (anti tumor necrosis factor inhibitor)
   Seoul National University Hospital
      2015   Phase 2   NCT02457585   Korea, Republic of;
RoActemra 20mg/ml
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 3   EUCTR2018-003753-13-FR   France;
Tocilizumab
    Clinical ImmunologySaitama Medical Center, Saitama Medical Universitity
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT04564001   -
      2014   Phase 3   NCT02101333   France;
   Department of Cardiovascular Medicine Graduate School of Medicine Osaka University
      2012   -   JPRN-UMIN000007845   Japan;
   Department of Rheumatology &
   Osaka University
      2017   -   JPRN-UMIN000025940   Japan;
   Osaka Unversity
      2014   -   JPRN-UMIN000025943   Japan;
   Shanghai Zhongshan Hospital
      2020   Phase 4   NCT04300686   China;
      2016   -   NCT03893136   China;
Tocilizumab (MRA-SC)
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 3   JPRN-JapicCTI-142616   Japan;
Tofacitinib
   Chinese SLE Treatment And Research Group
      2022   Phase 4   NCT05151848   China;
Tofacitinib tablet
   Shanghai Zhongshan Hospital
      2020   Phase 4   NCT04299971   China;
Upadacitinib
   AbbVie
      2020   Phase 3   NCT04161898   Japan;Korea, Republic of;Turkey;
Ustekinumab
   Janssen Pharmaceutical K.K.
      2021   Phase 3   NCT04882072   Japan;
   Numaguchi Hirotaka
      2021   Phase 3   JPRN-jRCT2061210007   Japan;
Yellow Fever vaccine (17D)
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil;